Evaluation of the Effect of Empagliflozin on Histological Changes of the Liver in Male Rats with Induced Diabetes

Amal  Mahmood Alwan; Raya  Zaid Ali; Abthal  Noori Mahdi; Aya  Azam Jamal; Dorees  Taher Hasan; WUROOD  KHALID MOHAMMED

doi:10.69923/sdjr6305

Authors

Amal Mahmood Alwan University of Diyala Author https://orcid.org/0009-0006-3475-4013
Raya Zaid Ali University of Diyala Author https://orcid.org/0009-0007-2613-3361
Abthal Noori Mahdi University of Diyala Author https://orcid.org/0009-0007-7270-2115
Aya Azam Jamal University of Diyala Author
Dorees Taher Hasan University of Diyala Author
WUROOD KHALID MOHAMMED University of Diyala Author

DOI:

https://doi.org/10.69923/sdjr6305

Keywords:

Empagliflozin drug, Hepatic histological changes, Alloxan, Liver histopathology, Type 2 diabetesType 2 diabetes

Abstract

Empagliflozin is a new class of antidiabetic drugs that are specific for the sodium and glucose transporter and are taken orally. It belongs to the gliflozin family, which works to suppress blood sugar levels and also has multiple anti-inflammatory effects. Diabetes is considered one of the health problems that is increasing in its growth rate in general throughout the world. The study aims to evaluate and know the effects of some type 2 antidiabetic drugs on the histological structure of the liver of male rats in which diabetes is induced. 15 adult male rats were used in this study and they were divided into two groups. The first group was the control group, which consisted of 5 male rats. The second group included 10 male rats. This group, in turn, was divided into two secondary groups, each group containing 5 male rats. Diabetes induced by alloxan, the first secondary group remained afflicted with induced diabetes without any treatment, while the second secondary group was treated with the drug Empagliflozin at a concentration of 5 mg/kg, which was dosed to the animals for 30 days and once every day. The results obtained included congestion of the central vein, irregularity of the hepatic cells in the form of ropes, enlargement of some hepatic cells, loss of nuclei in some cells and thickening of some nuclei in others, the appearance of edema, bleeding within the sinusoids, dilatation of the sinusoids, and infiltration of inflammatory cells. The beginning of the formation of fatty tissue.

Downloads

Download data is not yet available.

Author Biographies

Amal Mahmood Alwan, University of Diyala

Amal Mahmood Alwan is a lecturer in the Department of Biology, College of Education for Pure Sciences, University of Diyala, Iraq. She received their Ph.D. in Biological Sciences with a specialization in Animal Histology. Their research interests include animal histology, tissue pathology, experimental biology, and related areas of biology sciences. She has authored and coauthored several scientific publications in national and international journals. She can be contacted at amal.m.alwan@uodiyala.edu.iq. Google Scholar:
Raya Zaid Ali, University of Diyala

Raya Zaid Ali is a lecturer in the Department of Biology, College of Education for Pure Sciences, University of Diyala, Iraq. She holds a Ph.D. in Biology Science with a specialization in Immunogenetics from the University of Diyala. Her research interests include genetics, immunology, and physiology. She has published several scientific papers in their field. She can be contacted at raya.zaid@uodiyala.edu.iq
Abthal Noori Mahdi, University of Diyala

Abthal Noori Mahdi is an assistant lecturer at Department of Biology, College of Education for Pure Sciences, University of Diyala, Iraq. She specializes in animal histology within the field of biology sciences. Their academic interests include histology, cell biology, and laboratory sciences. She contributes to teaching and scientific activities in her department. She can be contacted at abthalnoori3@gmail.com
Aya Azam Jamal, University of Diyala

Aya Azam Jamal works at the College of Education for Pure Science, University of Diyala, Iraq, in the field of biology and laboratory sciences. She contributes to administrative and scientific activities within the college. Their professional interests include biology, laboratory sciences, and scientific research. She can be contacted at ayaazam08@gmail.com
Dorees Taher Hasan, University of Diyala

Doris Taher Hassan works at the College of Education for Pure Science, University of Diyala, Iraq, in the field of biology and laboratory sciences. She contributes to administrative and scientific activities within the college. Their professional interests include biology, laboratory sciences, and scientific research. She can be contacted at lwy88941@gmail.com
WUROOD KHALID MOHAMMED, University of Diyala

Wurood Khalid Mohammed works at the College of Education for Pure Science, University of Diyala, Iraq, in the field of biological and laboratory sciences. She contributes to administrative and scientific activities within the college. Their professional interests include biology, laboratory sciences, and scientific research. She can be contacted at Wroodkhaled89@gmail.com

References

[1] R. M. M. Khan, Z. J. Y. Chua, J. C. Tan, Y. Yang, Z. Liao, and Y. Zhao, "From pre-diabetes to diabetes: Diagnosis, treatments and translational research," Medicina, vol. 55, no. 9, p. 546, 2019, doi: 10.3390/medicina55090546.

[2] World Health Organization and International Diabetes Federation, Classification of Diabetes Mellitus. Geneva, Switzerland: World Health Organization, 2019.

[3] C. Faselis, A. Katsimardou, K. Imprialos, P. Deligkaris, M. Kallistratos, and K. Dimitriadis, "Microvascular complications of type 2 diabetes mellitus," Current Vascular Pharmacology, vol. 18, no. 2, pp. 117–124, 2020, doi: 10.2174/1570161117666190502103733.

[4] D. Moriconi et al., "Glomerular hyperfiltration predicts kidney function decline and mortality in type 1 and type 2 diabetes: A 21-year longitudinal study," Diabetes Care, vol. 46, no. 4, pp. 845–853, 2023, doi: 10.2337/dc22-2003.

[5] M. I. Harris, Diabetes in America. Bethesda, MD, USA: National Institutes of Health, 2013.

[6] American Diabetes Association, "Classification and diagnosis of diabetes: Standards of medical care in diabetes—2021," Diabetes Care, vol. 44, no. 1, pp. S15–S33, 2021, doi: 10.2337/dc21-S002.

[7] A. M. Ali et al., "Antidiabetic potency, antioxidant effects, and mode of actions of Citrus reticulata fruit peel hydroethanolic extract, hesperidin, and quercetin in nicotinamide/streptozotocin-induced Wistar diabetic rats," Oxidative Medicine and Cellular Longevity, vol. 2020, Art. no. 1730492, 2020, doi: 10.1155/2020/1730492.

[8] E. N. Gurzov and D. L. Eizirik, "Bcl-2 proteins in diabetes: Mitochondrial pathways of β-cell death and dysfunction," Trends in Cell Biology, vol. 21, no. 7, pp. 424–431, 2011, doi: 10.1016/j.tcb.2011.03.001.

[9] D. A. Cunha et al., "Death protein 5 and p53-upregulated modulator of apoptosis mediate endoplasmic reticulum stress–mitochondrial dialog triggering β-cell apoptosis," Diabetes, vol. 61, no. 11, pp. 2763–2775, 2012, doi: 10.2337/db12-0123.

[10] S. Steiner, "Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes," Zeitschrift für Gefäßmedizin, vol. 13, no. 1, pp. 17–18, 2016, doi: 10.1056/NEJMoa1504720.

[11] V. Quagliariello et al., "The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin," Cardiovascular Diabetology, vol. 20, Art. no. 150, 2021, doi: 10.1186/s12933-021-01346-y.

[12] R. Saad et al., "The molecular effects of SGLT2i empagliflozin on the autophagy pathway in diabetes mellitus type 2 and its complications," Journal of Diabetes Research, vol. 2022, Art. no. 8337823, pp. 1–11, 2022, doi: 10.1155/2022/8337823.

[13] J. Cai et al., "AMPK: The key to ischemia-reperfusion injury," Journal of Cellular Physiology, vol. 237, no. 11, pp. 4079–4096, 2022, doi: 10.1002/jcp.30875.

[14] K. Houguig, S. Rkha, M. Rayadi, and N. Ouzennou, "Factors influencing therapeutic observance in diabetic subjects in the province of Essaouira (Morocco): A cross-sectional study," Ethiopian Journal of Health Sciences, vol. 32, no. 4, pp. 747–754, 2022, doi: 10.4314/ejhs.v32i4.11.

[15] A. Elksnis, M. Martinell, O. Eriksson, and D. Espes, "Heterogeneity of metabolic defects in type 2 diabetes and its relation to reactive oxygen species and alterations in beta-cell mass," Frontiers in Physiology, vol. 10, Art. no. 107, 2019, doi: 10.3389/fphys.2019.00107.

[16] E. Sokolowska and A. Blachnio-Zabielska, "The role of ceramides in insulin resistance," Frontiers in Endocrinology, vol. 10, Art. no. 577, 2019, doi: 10.3389/fendo.2019.00577.

[17] Z. A. Jigheh et al., "Empagliflozin alleviates renal inflammation and oxidative stress in streptozotocin-induced diabetic rats partly by repressing HMGB1-TLR4 receptor axis," Iranian Journal of Basic Medical Sciences, vol. 22, no. 4, pp. 384–391, 2019, doi: 10.22038/ijbms.2019.31788.7651.

[18] I. A. Okafor, U. S. Nnamah, and J. Nnaka, "Liver function analyses and spleen histology assessment following the co-administration of cisplatin and methanolic extract of Portulaca oleracea in Wistar rats," Natural Product Sciences, vol. 26, no. 3, pp. 252–258, 2020, doi: 10.20307/nps.2020.26.3.252.

[19] E. Ferrari and M. Rasponi, "Liver–heart on chip models for drug safety," APL Bioengineering, vol. 5, no. 3, Art. no. 031504, 2021, doi: 10.1063/5.0048986.

[20] K. Reyes-Gordillo, R. Shah, and P. Muriel, "Oxidative stress and inflammation in hepatic diseases: Current and future therapy," Oxidative Medicine and Cellular Longevity, vol. 2017, Art. no. 3140673, 2017, doi: 10.1155/2017/3140673.

[21] N. Sandhu and V. Navarro, "Drug-induced liver injury in GI practice," Hepatology Communications, vol. 4, no. 5, pp. 631–645, 2020, doi: 10.1002/hep4.1503.

[22] C. Ronco and L. Di Lullo, "Cardiorenal syndrome," Heart Failure Clinics, vol. 10, no. 2, pp. 251–280, 2014.